[What is achieved by therapy of the nephrotic syndrome in adults?].
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000686:Amyloidosis / Q000150:complications; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D000941:Antigens; D002648:Child; D002675:Child, Preschool; D048909:Diabetes Complications; D005921:Glomerulonephritis / Q000150:complications; D006331:Heart Diseases / Q000150:complications; D006801:Humans; D011695:IgA Vasculitis / Q000150:complications; D007223:Infant; D008180:Lupus Erythematosus, Systemic / Q000150:complications; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000209:etiology; D012082:Renal Veins; D013256:Steroids / Q000627:therapeutic use; D013927:Thrombosis / Q000150:complications
D000900:Anti-Bacterial Agents; D000925:Anticoagulants; D000941:Antigens; D013256:Steroids
Was ist gesichert in der Therapie des nephrotischen Syndroms im Erwachsenenalter